Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure - 09/08/11
for the Get With the Guidelines Steering Committee and Hospitals
Résumé |
Background |
In chronic heart failure (HF), lower total cholesterol (TC) levels have been associated with increased mortality. However, the relationship between lipid levels and outcomes in acute HF has not been studied. This study investigates the relationship between cholesterol levels and in-hospital mortality in patients hospitalized with acute HF.
Methods |
The Get With the Guidelines–Heart Failure registry prospectively collects data on patients hospitalized with HF. We analyzed data on 17,791 patients admitted between January 2005 and June 2007 at 236 participating hospitals who had TC levels recorded. Baseline patient characteristics, treatment regimens, and in-hospital mortality were examined by TC level (mg/dL) quartiles (Q) as follows: Q1 (TC ≤118), Q2 (TC 119-145), Q3 (TC 146-179), and Q4 (TC ≥180).
Results |
Mean TC level was 150 ± 47 mg/dL. Patients with lower TC were older and had higher prevalence of ischemic heart disease. Of the patients, 46% were on a lipid-lowering drug, including 58%, 50%, 43%, and 34% of patients in TC Q1 to Q4, respectively. In-hospital mortality in TC Q1 to Q4 was 3.3%, 2.5%, 2.0%, and 1.3%, respectively (P < .0001). On multivariable adjusted analyses, each 10-mg/dL increase in TC level was associated with 4% decreased risk of in-hospital mortality (odds ratio 0.96, 95% CI 0.93-0.98).
Conclusions |
In patients hospitalized with HF, lower TC levels independently predict increased in-hospital mortality risk. Further evaluation of optimal cholesterol levels and influence of lipid-lowering medication use on outcomes in this population is warranted.
Le texte complet de cet article est disponible en PDF.Plan
| This study was funded by the American Heart Association (Dallas, TX) with support from an unrestricted educational grant from GlaxoSmithKline (Philadelphia, PA). Dr Horwich is supported by the National Institutes of Health 1K23HL085097 (Bethesda, MD). Dr Hernandez is a recipient of an American Heart Association Pharmaceutical Roundtable grant (0675060N) and a research support from GlaxoSmithKline. Dr Horwich has no funding/support to disclose; Dr Dai is an employee of Duke Clinical Research Institute (Durham, NC); Drs Yancy and Fonarow engage in research and are consultants in GlaxoSmithKline and received honorarium from the same company; Dr Fonarow is the chair of the Get With the Guidelines Steering Committee, and holds the Eliot Corday Chair in Cardiovascular Medicine and Science. |
Vol 156 - N° 6
P. 1170-1176 - décembre 2008 Retour au numéro
Article précédent
- Cigarette smoking and risk of atrial fibrillation: The Rotterdam Study
- Jan Heeringa, Jan A. Kors, Albert Hofman, Frank J.A. van Rooij, Jacqueline C.M. Witteman
- A cardiopulmonary exercise testing score for predicting outcomes in patients with heart failure
- Jonathan Myers, Ross Arena, Frederick Dewey, Daniel Bensimhon, Joshua Abella, Leon Hsu, Paul Chase, Marco Guazzi, Mary Ann Peberdy
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?